Senseonics Holdings, Inc. Announces Collaboration with the University Hospitals Accountable Care Organization in Cleveland, Ohio
September 13, 2021 at 04:05 pm EDT
Share
Senseonics Holdings, Inc. have announced that the University Hospitals Accountable Care Organization (UHACO) in Cleveland, Ohio has begun offering the Eversense® CGM System to its Medicare enrollees effective early September, 2021. The recent decision to use the Eversense CGM System in eligible patients with type 1 diabetes or type 2 diabetes on insulin shows the commitment of UHACO to facilitate optimal diabetes management for its enrollees. The Eversense CGM System consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app for displaying glucose values, trends and alerts. In addition to featuring the first long-term and first implantable CGM sensor, the system is also first to feature a smart transmitter that provides wearers with discreet on-body vibratory alerts for high and low glucose and can be removed, recharged and re-attached to the skin without discarding the sensor The sensor is inserted subcutaneously in the upper arm by a health care provider via a brief in-office procedure.
Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems, Eversense, Eversense XL, and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every five minutes to a mobile app on the user's smartphone. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device. Its CGM system continually and accurately measures a person's glucose levels for up to six months.